Search Results - "Guy De La Rosa"

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients by Man-fung Yuen, Wan-long Chuang, Cheng-yuan Peng, Wen-juei Jeng, Wei-wen Su, Ting-tsung Chang, Chi-yi Chen, Yao-chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

“…Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in…”
Get full text

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial by Jacobson, Ira M, Prof, Dore, Gregory J, Prof, Foster, Graham R, Prof, Fried, Michael W, Prof, Radu, Monica, MD, Rafalsky, Vladimir V, Prof, Moroz, Larysa, Prof, Craxi, Antonio, Prof, Peeters, Monika, MSc, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, De La Rosa, Guy, MD, Kalmeijer, Ronald, MD, Scott, Jane, PhD, Sinha, Rekha, PhD, Beumont-Mauviel, Maria, PhD

“…Summary Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus…”
Get full text

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study by Kwo, Paul, Gitlin, Norman, Nahass, Ronald, Bernstein, David, Etzkorn, Kyle, Rojter, Sergio, Schiff, Eugene, Davis, Mitchell, Ruane, Peter, Younes, Ziad, Kalmeijer, Ronald, Sinha, Rekha, Peeters, Monika, Lenz, Oliver, Fevery, Bart, De La Rosa, Guy, Scott, Jane, Witek, James

“…Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)‐infected patients. The phase 2 COSMOS…”
Get full text

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial by Manns, Michael, Prof, Marcellin, Patrick, Prof, Poordad, Fred, Prof, de Araujo, Evaldo Stanislau Affonso, PhD, Buti, Maria, Prof, Horsmans, Yves, Prof, Janczewska, Ewa, MD, Villamil, Federico, Prof, Scott, Jane, PhD, Peeters, Monika, MSc, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, De La Rosa, Guy, MD, Kalmeijer, Ronald, MD, Sinha, Rekha, PhD, Beumont-Mauviel, Maria, PhD

“…Summary Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus…”
Get full text

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor by Rosenquist, Åsa, Samuelsson, Bertil, Johansson, Per-Ola, Cummings, Maxwell D., Lenz, Oliver, Raboisson, Pierre, Simmen, Kenny, Vendeville, Sandrine, de Kock, Herman, Nilsson, Magnus, Horvath, Andras, Kalmeijer, Ronald, de la Rosa, Guy, Beumont-Mauviel, Maria

“…Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation. Since…”
Get full text

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients by Yuen, Man-Fung, Chuang, Wan-Long, Peng, Cheng-Yuan, Jeng, Wen-Juei, Su, Wei-Wen, Chang, Ting-Tsung, Chen, Chi-Yi, Hsu, Yao-Chun, De La Rosa, Guy, Ahmad, Alaa, Luo, Ed, Conery, Annie L

“…Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric…”
Get full text

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy by Li, Jonathan Z, Chapman, Brad, Charlebois, Patrick, Hofmann, Oliver, Weiner, Brian, Porter, Alyssa J, Samuel, Reshmi, Vardhanabhuti, Saran, Zheng, Lu, Eron, Joseph, Taiwo, Babafemi, Zody, Michael C, Henn, Matthew R, Kuritzkes, Daniel R, Hide, Winston, Wilson, Cara C, Berzins, Baiba I, Acosta, Edward P, Bastow, Barbara, Kim, Peter S, Read, Sarah W, Janik, Jennifer, Meres, Debra S, Lederman, Michael M, Mong-Kryspin, Lori, Shaw, Karl E, Zimmerman, Louis G, Leavitt, Randi, De La Rosa, Guy, Jennings, Amy

“…The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput…”
Get full text

Impact of Timing of Diagnosis of Respiratory Syncytial Virus (RSV) Disease on Hospital Length of Stay (LOS) in Adults: Final Analysis from a Retrospective Chart Review Study by Lee, Nelson, Walsh, Edward, Sander, Ian, Stolper, Robert, Zakar, Jessica, Rosa, Guy De La, Wyffels, Veronique, Myers, David, Fleischhackl, Roman

“…Abstract Background Despite growing clinical awareness of RSV disease in at-risk adult subpopulations, significant gaps remain in knowledge, especially around…”
Get full text

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial by Mrus, Joseph, Anderson, David, Ryan, Robert, De La Rosa, Guy, Coate, Bruce, Vis, Peter, Kakuda, Thomas, Sekar, Vanitha

“…Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by…”
Get full text

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks by Currier, Judith S, Martorell, Claudia, Osiyemi, Olayemi, Yin, Michael T, Ryan, Robert, De La Rosa, Guy, Mrus, Joseph

“…Gender-based differences in lipids have been noted in antiretroviral clinical trials. We present the metabolic and anthropometric data from the GRACE (Gender,…”
Get more information

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2) by Lawitz, Eric, Matusow, Gary, DeJesus, Edwin, Yoshida, Eric M., Felizarta, Franco, Ghalib, Reem, Godofsky, Eliot, Herring, Robert W., Poleynard, Gary, Sheikh, Aasim, Tobias, Hillel, Kugelmas, Marcelo, Kalmeijer, Ronald, Peeters, Monika, Lenz, Oliver, Fevery, Bart, De La Rosa, Guy, Scott, Jane, Sinha, Rekha, Witek, James

“…Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of hepatic decompensation. In the…”
Get full text

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial by Forns, Xavier, Lawitz, Eric, Zeuzem, Stefan, Gane, Ed, Bronowicki, Jean Pierre, Andreone, Pietro, Horban, Andrzej, Brown, Ashley, Peeters, Monika, Lenz, Oliver, Ouwerkerk–Mahadevan, Sivi, Scott, Jane, De La Rosa, Guy, Kalmeijer, Ronald, Sinha, Rekha, Beumont–Mauviel, Maria

“…Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir…”
Get full text

EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients by Yuen, Man-Fung, Chuang, Wan-Long, Peng, Cheng-Yuan, Jeng, Rachel Wen-Juei, Su, Wei-Wen, Chang, Ting-Tsung, Chen, Chi-Yi, Hsu, Yao-Chun, De Rosa La, Guy, Ahmad, Alaa, Luo, Ed, Conery, Annie, Adda, Nathalie

Get full text

EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients by Feld, Jordan, Lawitz, Eric, Nguyen, Tuan T, Lalezari, Jacob P, Hassanein, Tarek, Martin, Paul, Han, Steven-Huy B, Dieterich, Douglas T, Giard, Jeanne-Marie, De La Rosa, Guy, Ahmad, Alaa, Luo, Ed, Conery, Annie, Adda, Nathalie

Get full text

Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study by Dieterich, Douglas, Rockstroh, Jürgen Kurt, Orkin, Chloe, Gutiérrez, Félix, Klein, Marina B., Reynes, Jacques, Shukla, Umesh, Jenkins, Alan, Lenz, Oliver, Ouwerkerk-Mahadevan, Sivi, Peeters, Monika, De La Rosa, Guy, Tambuyzer, Lotke, Jessner, Wolfgang

“…Background. Simeprevir is an oral, once-daily, hepatitis C virus (HCV) NS3/4A protease inhibitor for the treatment of chronic HCV genotype 1 infection. Human…”
Get full text

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks by Aberg, Judith A, Tebas, Pablo, Overton, Edgar Turner, Gupta, Samir K, Sax, Paul E, Landay, Alan, Falcon, Ron, Ryan, Robert, De La Rosa, Guy

“…We assessed metabolic changes for darunavir/ritonavir (DRV/r) once daily (qd) versus atazanavir/ritonavir (ATV/r) qd with fixed-dose tenofovir/emtricitabine…”
Get more information

Native Valve Endocarditis Due to Bartonella henselae in a Middle-Aged Human Immunodeficiency Virus-Negative Woman by DE LA ROSA, Guy R, BARNETT, Ben J, ERICSSON, Charles D, TURK, Jeffrey B

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A Case of Strongyloides stercoralis and Mesenteric Tuberculous Infection with Acute Abdominal Pain in an HIV-positive Patient by Guy R. de la Rosa, Kuliev, Agadadash, Barnett, Ben J.

“…We describe an HIV-positive female patient who had acute abdominal pain as the initial presentation of Strongyloides stercoralis infection. The diagnosis was…”
Get full text

Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial by Lundgren, Jens, Babiker, Abdel, Gordin, Fred, Emery, Sean, Fätkenheuer, Gerd, Molina, Jean-Michel, Wood, Robin, Neaton, James D

Get full text

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients by Lathouwers, Erkki, De La Rosa, Guy, Van de Casteele, Tom, Baeten, Benny, Tomaka, Frank, De Meyer, Sandra, Picchio, Gaston

“…The aim of this analysis was to characterize viral resistance in the Phase III, randomized ODIN trial, which demonstrated non-inferiority of once-daily…”
Get more information